New Study Demonstrates Inferior Vena Cava Filters Are Safe & Effective Way to Treat Venous Thromboembolism

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • “DVTs and PEs are a significant cause of death worldwide and understanding fully how tools like IVC filters can be used to prevent the progression of a DVT into a PE allow physicians to safely treat patients at risk of death from VTE,” said David L Gillespie, MD, FACS, a vascular surgeon at Beth Israel Deaconess Medical Center in Brockton, Massachusetts, and co-principal investigator on PRESERVE.
  • Few adverse events are connected to the use of inferior vena cava (IVC) filters to help prevent deep vein blood clots from developing into pulmonary embolisms (PE), according to the findings of the Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) trial, published jointly in the Journal of Vascular and Interventional Radiology (JVIR) and the Journal of Vascular Surgery Venous and Lymphatics (JVSVL).
  • ' but ‘how should we offer comprehensive filter-inclusive care of patients with venous blood clots, comprised of a detailed patient evaluation, a plan for retrieval after placement, and frequent follow up with evaluation for filter removal or replacement,'” said Matthew S.

Few adverse events are connected to the use of inferior vena cava (IVC) filters to help prevent deep vein blood clots from developing into pulmonary embolisms (PE), according to the findings of the Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) trial, published jointly in the Journal of Vascular and Interventional Radiology (JVIR) and the Journal of Vascular Surgery Venous and Lymphatics (JVSVL).

PRESERVE is an FDA-directed multicenter, prospective, open-label, non-randomized trial that studied the safety and efficacy of IVC filters from six manufacturers. It was a joint effort of the Society of Interventional Radiology (SIR) and the Society for Vascular Surgery (SVS). The study was conducted at 54 sites in the United States between Oct. 10, 2015, and March 31, 2019. During that time, filters were implanted in 1,421 patients, of which 1,019 patients had an existing deep vein thrombosis (DVT) or pulmonary embolism (PE).

Researchers found that IVC filters were effective in helping to prevent PEs in patients experiencing a DVT where anticoagulation medicines failed or were not an option for the patient. Approximately half of the patients in the study had their filters removed within 3 months of placement without complication or recurrence of DVT or PE, according to study authors.

“The question shouldn’t be only ‘should we place a filter?’ but ‘how should we offer comprehensive filter-inclusive care of patients with venous blood clots, comprised of a detailed patient evaluation, a plan for retrieval after placement, and frequent follow up with evaluation for filter removal or replacement,’” said Matthew S. Johnson, MD, FSIR, an interventional radiologist and professor of radiology and surgery at Indiana University School of Medicine in Indianapolis and co-principal investigator on PRESERVE. “PRESERVE showed what questions we should ask as clinicians: ‘does this person continue to require protection against PE, and, in light of changing clinical status and available therapies, is the current filter needed?’ and then make an informed decision on how to continue care.”

“DVTs and PEs are a significant cause of death worldwide and understanding fully how tools like IVC filters can be used to prevent the progression of a DVT into a PE allow physicians to safely treat patients at risk of death from VTE,” said David L Gillespie, MD, FACS, a vascular surgeon at Beth Israel Deaconess Medical Center in Brockton, Massachusetts, and co-principal investigator on PRESERVE. “Now that the study is complete, we now have a roadmap for better filter utilization. We need to solidify a clearer set of practice guidelines for venous thromboembolic disease, based on its symptoms, location and complications. Further studies will focus on how the different manifestations of venous thromboembolic disease may benefit from filter-inclusive care.”

To date, PRESERVE is the largest prospective study investigating the real-world patient outcomes of IVC filter use.

“This trial represents an important step in collaborating across specialties to benefit the health and safety of our patients,” said SIR President Parag J. Patel, MD, MS, FSIR. “Thanks to the work of Drs. Johnson and Gillespie and all the investigators and patients involved in the trial, we now have higher quality evidence to support appropriate utilization and management of IVC filters in patients with venous thromboembolic disease.”

“Congratulations to Dr. Gillespie, Dr. Johnson and their many colleagues for shepherding this large collaborative multi-specialty, multi-center clinical trial to completion,” said Michael C. Dalsing, MD, president of the Society for Vascular Surgery. “This highly impactful study provides the real-world evidence needed when recommending IVC filter placement to protect our patients from a potentially lethal disease and when to remove that filter after it has accomplished the desired effect. It is a stellar example of collaboration across specialties for the betterment of patient care.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Sedana Medical Completes Patient Recruitment for its Clinical Program in the US

"The completion of INSPiRE-ICU 2 concludes Sedana Medical´s clinical trials in the United States. Running this study together with esteemed clinical investigators from highly ranked academic centers such as Columbia, the Harvard-affiliated medical center Beth Israel Deaconess Medical Center and many others has been very exciting and rewarding. Many investigators from the participating sites have been excited to be part of our pioneering studies. The bedside experience in the studies has generated a lot of interest in using inhaled sedation in US practice, which we hope will be possible soon," said Peter Sackey, Chief Medical Officer of Sedana Medical.

By using this website you agree to accept Medical Device News Magazine Privacy Policy